NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11.3 mln
Float1.54 mln
Earnings Date08/18/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
10.50
Transformational upside
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
-6.07
Negative equity
ROE
-1,088
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
CalciMedica is a clinical-stage company working to develop new treatments for serious conditions driven by inflammation, immune system dysfunction, and direct damage to cells. Its primary drug, Auxora, is given intravenously and works by blocking a specific calcium channel in the body, targeting conditions such as acute pancreatitis, kidney injury, and severe COVID-19 pneumonia. The company is also exploring Auxora as a potential therapy for ulcerative colitis, traumatic brain injury, and allergic asthma, while developing oral medications for longer-term inflammatory and immune-related diseases. CalciMedica is headquartered in La Jolla, California.
